- The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) increased by over 10% pre-market today. This is why it happened.
The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) – a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders – increased by over 10% pre-market today. Investors are responding positively to Inhibikase Therapeutics announcing the publication of a paper describing the biochemical rationale and potential benefit of Abelson Tyrosine Kinase (c-Abl) inhibition as a potential disease-modifying therapy for Parkinson’s Disease. The article – titled “Parkinson’s Disease Modification Through Abl Kinase Inhibition: An Opportunity” – was published online in the journal Movement Disorders on November 24, 2021 (DOI: 10/1002/mds.28858).
The publication analyzed the role of both c-Abl, a non-receptor tyrosine kinase, as well as misfolded alpha-synuclein in the initiation and progression of Parkinson’s disease (PD). And early research in PD hypothesized that misfolded alpha-synuclein was the primary driver in initiating the disease process.
But novel humanized preclinical mouse models of progressive alpha-synuclein-dependent disease indicate that while the presence of misfolded alpha-synuclein is necessary, it is not sufficient to initiate the disease. And the internalization of misfolded alpha-synuclein within the affected neurons activates c-Abl, which in turns modifies the internalized misfolded protein to create a toxic form of alpha-synuclein and triggering effectors that drive the neurodegenerative disease processes.
The therapeutic administration of IkT-148009, a highly selective c-Abl kinase inhibitor, demonstrated the ability to clear alpha-synuclein aggregates from the brain and GI tract, promote regeneration of neurons, and induce substantial functional recovery in measures of motor and non-motor function. And these studies support that the inhibition of c-Abl could have disease modifying effects and further support the continued clinical development of IkT-148009.
“Parkinson’s disease affects an estimated one million people in the U.S. and remains a significant unmet medical need. Today’s publication provides a detailed mechanistic understanding of the early steps in the disease process and the role c-Abl plays in neurodegeneration. Our lead candidate, IkT-148009, a selective c-Abl kinase inhibitor, has demonstrated the potential to halt and reverse disease progression in animal models. IkT-148009 is currently in a Phase 1b extension study in Parkinson’s patients, which we believe will give us an early look into safety and tolerability of IkT-148009 in patients and evaluate potential improvements across motor and non-motor aspects of the disease in patients over 7-day dosing. We anticipate completing this extension study in 2022, and expect to present data from our Phase 1 and possibly Phase 1b studies at the AD-PD Meeting to be held March 15-20, 2022 in Barcelona, Spain.”
— Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics and principal author of the manuscript published along with co-author and Interim Chief Medical Officer Dr. Warren Olanow
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.